Table 2.

Clinical profile, treatment and outcome of present cases with previously published cases

Ref no	Age	Sex	Respiratory symptoms	Others	Outcome
14	68	F	Unusual dyspnoea	NA	Improved
15	58	F	NA	mPSL, PSL, IVCY, IVIg, PMX	Improved
16	55	F	Respiratory failure	CPA, PE	Died
17	71	F	Respiratory failure	PSL, Tac	improved
18	71	F	Respiratory failure	mPSL, PSL, CsA, MMF, Tac	Died
18	69	F	Respiratory failure	mPSL, PSL, CsA, IVCY, tocilizumab, CHD PSL,	Died
19	48	M	Respiratory failure	PSL, CsA	Improved
Present case1	37*	F	Respiratory failure	mPSL, RTX, IVIg	Died
Present case2	42*	F	Respiratory failure	mPSL, RTX	Died

CHD, continuous hemodiafiltration; CPA, cyclophosphamide; CsA, Ciclosporin A; F, female; IVCY, intravenous cyclophosphamide; M, male; MMF, mycophenolate mofetil; mPSL, methylprednisolone; NA, not available; PE, plasma exchange; PMX, polymyxin B; PSL, prednisolone; RTX, rituximab; Tac, tacrolimus.